Abstract: The present disclosure provides a method for forwarding a packet. When an access point (AP) receives a first packet from a wireless station, the AP may tunnel encapsulate the first packet and send the first packet through a tunnel to a switch which is designated for the AP by an access controller (AC). When the AP receives a packet from the switch through the tunnel, the AP may tunnel de-capsulate the packet to acquire a second packet, and send the second packet to the wireless station according to a forward table.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: According to an example, in an AC pool including a MAC and a plurality of LACs registered on the MAC, after a first LAC is registered on the MAC, the MAC issues a first traffic rule to the first LAC, wherein the first traffic rule redirects a discovery packet sent from an AP to the MAC. When receiving the discovery packet sent from the AP or receiving a discovery packet sent from the AP and forwarded via a LAC, the MAC selects, from a plurality of the LACs, a second LAC for handling the AP. The MAC generates a second traffic rule associated with the AP and the second LAC, and issue the second traffic rule to a plurality of the LACs, so that when another LAC receives a communication tunnel protocol packet sent from the AP, the other LAC redirects the communication tunnel protocol packet to the second LAC.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: According to an example, in an AC pool including a MAC and a plurality of LACs registered on the MAC, after a first LAC is registered on the MAC, the MAC issues a first traffic rule to the first LAC, wherein the first traffic rule redirects a discovery packet sent from an AP to the MAC. When receiving the discovery packet sent from the AP or receiving a discovery packet sent from the AP and forwarded via a LAC, the MAC selects, from a plurality of the LACs, a second LAC for handling the AP. The MAC generates a second traffic rule associated with the AP and the second LAC, and issue the second traffic rule to a plurality of the LACs, so that when another LAC receives a communication tunnel protocol packet sent from the AP, the other LAC redirects the communication tunnel protocol packet to the second LAC.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: The present application describes modulators of chemokine receptor activity of formula I or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

Abstract: The present application describes modulators of chemokine receptor activity of formula I or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

Abstract: The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

Abstract: The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

Abstract: A method and apparatus for operating logic circuitry with recycled energy. Logic circuitry is used which has a node for storing energy and a return node that is connected to energy storage circuitry. The logic circuitry operates, using energy stored on the node, to determine a logic output based on a logic input during a first phase. The energy storage circuitry capture a portion of the stored energy during the operation of the logic circuitry and transfers a portion of the captured energy back to the node during a second phase. The energy storage circuitry oscillates with a determinable period and is tunable so that its oscillations can be synchronized to a clock.

Abstract: A method and apparatus for operating logic circuitry with recycled energy. Logic circuitry is used which has a node for storing energy and a return node that is connected to energy storage circuitry. The logic circuitry operates, using energy stored on the node, to determine a logic output based on a logic input during a first phase. The energy storage circuitry capture a portion of the stored energy during the operation of the logic circuitry and transfers a portion of the captured energy back to the node during a second phase. The energy storage circuitry oscillates with a determinable period and is tunable so that its oscillations can be synchronized to a clock.

Abstract: A method and aparatus for operating logic circuitry with recycled energy. Logic circuitry is used which has a node for storing energy and a return node that is connected to energy storage circuitry. The logic circuitry operates, using energy stored on the node, to determine a logic output based on a logic input during a first phase. The energy storage circuitry capture a portion of the stored energy during the operation of the logic circuitry and transfers a portion of the captured energy back to the node during a second phase. The energy storage circuitry oscillates with a determinable period and is tunable so that its oscillations can be synchronized to a clock.

Abstract: A method and apparatus for operating logic circuitry with recycled energy. Logic circuitry is used which has a node for storing energy and a return node that is connected to energy storage circuitry. The logic circuitry operates, using energy stored on the node, to determine a logic output based on a logic input during a first phase. The energy storage circuitry capture a portion of the stored energy during the operation of the logic circuitry and transfers a portion of the captured energy back to the node during a second phase. In one embodiment, the logic circuitry and the energy storage circuitry form a resonant circuit and the logic circuitry operates synchronously to a clock. In another embodiment, the energy storage circuitry includes a resonant circuit configured to oscillate with a determinable period. The resonant circuit is tunable so that its oscillations can be synchronized to a clock.